Order Article Reprints

Aicher A, Sindrilaru A, Crisan D, Thaiss W, Steinacker J, Beer M, Wiegel T, Scharffetter-Kochanek K, Beer AJ, Prasad V. Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics. 2022; 14(7):1466. https://doi.org/10.3390/pharmaceutics14071466

Aicher, Alexandra, Anca Sindrilaru, Diana Crisan, Wolfgang Thaiss, Jochen Steinacker, Meinrad Beer, Thomas Wiegel, Karin Scharffetter-Kochanek, Ambros J. Beer, and Vikas Prasad. 2022. "Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma" Pharmaceutics 14, no. 7: 1466. https://doi.org/10.3390/pharmaceutics14071466

Aicher, A., Sindrilaru, A., Crisan, D., Thaiss, W., Steinacker, J., Beer, M., Wiegel, T., Scharffetter-Kochanek, K., Beer, A. J., & Prasad, V. (2022). Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics, 14(7), 1466. https://doi.org/10.3390/pharmaceutics14071466